Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAIR platform study of rilvegostomig-based combinations in advanced or metastatic non-small cell lung cancer
NL-OMON61032Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of rilvegostomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability in Part A safety run-in, Safety and tolerability in Part B dose expansion and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61032.